https://www.selleckchem.com/products/mli-2.html
This study aims to develop and validate a simple score to estimate survival in the older population suffering from malignant hemopathies. We prospectively recruited 285 patients, aged ≥65years, admitted to receive chemotherapy. At inclusion, a geriatric assessment was performed. Cox proportional hazards models were performed to assess correlations between vulnerabilities and one-year survival. We developed a frailty score, HEMA-4, based on the most powerful prognostic factors. It was externally confirmed with an independent cohort. In the
Like
Comment
Share
